|
Studied endpoint for hMG versus r-hFSH
|
MD
|
95% CI
|
p value
|
SDM
|
95% CI
|
P value
|
|---|
|
Number of oocytes
| | | | | | |
|
- Main analysis
|
-1.54
|
-2.53, -0.56
|
< 0.0001
|
-0.23
|
-0.36, -0.10
|
< 0.0001
|
|
- Sub-group 1
|
-1.68
|
-2.69, -0.68
|
< 0.0001
|
-0.25
|
-0.38, -0.12
|
< 0.0001
|
|
- Sub-group 2
|
-1.57
|
-2.65, -0.49
|
< 0.001
|
-0.24
|
-0.38, -0.11
|
< 0.0001
|
|
- Main analysis (fixed model)
|
-1.74
|
-2.12, -1.35
|
< 0.0001
|
-0.26
|
-0.32, -0.19
|
< 0.0001
|
|
Number of oocytes adjusted for baseline
|
-2.10
|
-2.83, -1.36
|
< 0.001
|
-0.35
|
-0.47, -0.22
|
< 0.0001
|
|
Dosage (IU)
|
235.46
|
16.62, 454.30
|
0.03
|
0.33
|
0.08, 0.58
|
0.01
|
- hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; MD = mean difference; SDM = standardized mean difference
